TELA Bio (TELA) Cash from Operations Growth (3y) (2021 - 2026)
TELA Bio (TELA) Cash from Operations Growth (3y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.48 Bn | 176.19 Bn | 6.27 Bn | 4.78% |
| 2 | Stryker | 129.11 Bn | 126.23 Bn | 3.81 Bn | 9.30% |
| 3 | Medtronic | 108.35 Bn | 99.13 Bn | 6.41 Bn | 1.51% |
| 4 | Boston Scientific | 68.68 Bn | 67.22 Bn | 3.61 Bn | 22.35% |
| 5 | Edwards Lifesciences | 48.35 Bn | 44.67 Bn | 1.29 Bn | -48.14% |
| 6 | Dexcom | 28.38 Bn | 27.26 Bn | 750.30 Mn | 50.11% |
| 7 | GE HealthCare Technologies | 28.04 Bn | 25.76 Bn | 1.98 Bn | -14.75% |
| 8 | Smith & Nephew | 26.92 Bn | 26.35 Bn | - | - |
| 9 | Koninklijke Philips | 24.06 Bn | 20.93 Bn | 2.07 Bn | 0.50% |
| 10 | TELA Bio | 38.25 Mn | -1.29 Mn | 12.52 Mn | 1.18% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.18% |
| Dec 31, 2025 | 23.74% |
| Sep 30, 2025 | 9.24% |
| Jun 30, 2025 | 12.22% |
| Mar 31, 2025 | 2.31% |
| Dec 31, 2024 | 7.73% |
| Sep 30, 2024 | -10.65% |
| Jun 30, 2024 | -23.86% |
| Mar 31, 2024 | -18.77% |
| Dec 31, 2023 | -15.87% |
| Sep 30, 2023 | -23.60% |
| Jun 30, 2023 | -21.02% |
| Mar 31, 2023 | -16.57% |
| Dec 31, 2022 | -15.20% |
| Sep 30, 2022 | -12.61% |
| Jun 30, 2022 | -30.94% |
| Mar 31, 2022 | -10.28% |
| Dec 31, 2021 | -18.49% |